These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7513377)

  • 1. How far should we investigate and treat prostate cancer? A lawyer's perspective.
    Gerber P
    Med J Aust; 1994 Apr; 160(8):523-4. PubMed ID: 7513377
    [No Abstract]   [Full Text] [Related]  

  • 2. An educational workshop on the early detection of prostate cancer--a before-after evaluation.
    Steginga SK; Pinnock C; Baade PD; Jackson C; Green A; Preston J; Heathcote P; McAvoy B
    Aust Fam Physician; 2005 Oct; 34(10):889-91. PubMed ID: 16217583
    [No Abstract]   [Full Text] [Related]  

  • 3. Mental competence, treatment and substitute consent: a lawyer's perspective.
    Evans K
    Health Law Can; 1988; 8(4):96-9. PubMed ID: 10312624
    [No Abstract]   [Full Text] [Related]  

  • 4. Consent before testing men for prostate cancer--a challenge?
    Hirst G
    Aust Fam Physician; 2005 Oct; 34(10):888. PubMed ID: 16217582
    [No Abstract]   [Full Text] [Related]  

  • 5. Making an informed choice about PSA screening.
    Ward J; Gattellari M
    Aust Fam Physician; 2001 Jul; 30(7):715-6. PubMed ID: 11558209
    [No Abstract]   [Full Text] [Related]  

  • 6. Screening for prostate cancer in 2006: PSA in the 21st century.
    Maroni PD; Crawford ED
    N C Med J; 2006; 67(2):136-9. PubMed ID: 16752718
    [No Abstract]   [Full Text] [Related]  

  • 7. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.
    Hammerer PG; Kattan MW; Mottet N; Prayer-Galetti T
    BJU Int; 2006 Jul; 98(1):11-9. PubMed ID: 16566811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening: a place for informed consent?
    Glodé LM
    Hosp Pract (Off Ed); 1994 Sep; 29(9):8, 11-2. PubMed ID: 7521881
    [No Abstract]   [Full Text] [Related]  

  • 9. [Legal (liability) aspects of PSA determination].
    Mielke K
    Urologe A; 2006 Jun; 45(6):756-65. PubMed ID: 16788794
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostatic punch biopsy].
    Braun M; Engelmann U
    Aktuelle Urol; 2006 Jul; 37(4):291-302. PubMed ID: 16897646
    [No Abstract]   [Full Text] [Related]  

  • 12. Advancing prostate cancer: treatment options for the urologist.
    Lowrance WT; Chang SS
    Urol Clin North Am; 2006 May; 33(2):211-7, vii. PubMed ID: 16631459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of informed consent on patient interest in prostate-specific antigen screening.
    Wolf AM; Nasser JF; Wolf AM; Schorling JB
    Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 15. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].
    Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E
    Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer and PSA screening.
    Mameghan H
    Aust Fam Physician; 1999 Aug; 28(8):777-81. PubMed ID: 10495525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Informed consent for PSA testing.
    Brown V
    J Fam Pract; 1996 Sep; 43(3):234-5. PubMed ID: 8797747
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management].
    Malmström PU
    Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565
    [No Abstract]   [Full Text] [Related]  

  • 19. A charting tool for estimating the PSA doubling time in patients with prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):315-6. PubMed ID: 16820269
    [No Abstract]   [Full Text] [Related]  

  • 20. Expectant management of prostate cancer--the author replies.
    Griffin AS
    N C Med J; 2000; 61(1):377. PubMed ID: 10647252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.